The Journal of Immunology, Vol 147, Issue 1 60-69, Copyright © 1991 by American Association of Immunologists

ARTICLES

Trispecific F(ab')3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells

A Tutt, GT Stevenson and MJ Glennie
Tenovus Research Laboratory, General Hospital, Southampton, United Kingdom.

To investigate whether the retargeting of resting CTL can benefit from cooperative signaling between the TCR/CD3 complex and various accessory molecules, such as CD2, CD4, CD5, and CD8, we have constructed a series of trispecific F(ab')3 derivatives. Each derivative was designed to engage effector T lymphocytes with two Fab' arms, and tumor cells with a single Fab' arm. They were constructed by selective coupling of three mAb Fab' fragments, primarily via their hinge-region sulfhydryl groups, using the cross-linker o-phenylenedimaleimide. En route to the production of trispecific F(ab')3 antibodies a range of bispecific F(ab')2 derivatives was first prepared which could bind simultaneously to two different receptor molecules on T cells. Bispecific derivatives containing specificities for (CD2 (T11(1)) x CD3), (CD3 x CD4), (CD3 x CD8) or two epitopes on CD2, ((T11(1) x (T11(3)), all yielded two to three times the uptake of [3H]thymidine with fresh PBMC to that seen with intact IgG from anti-CD3 (OKT3). The exception to these findings was a bispecific F(ab')2 derivative with specificities for (CD3 x CD5) which caused slightly less proliferation than the control reagent, OKT3 IgG. When these bispecific antibodies were converted into trispecific antibodies (TsAb) by the addition of a Fab' from anti-CD37 they were then all able to retarget resting, unprimed, T cells from fresh PBMC for lysis of CD37+ tumor cells. However, the cytotoxic activity of these reagents fell into two distinct groups: group one, containing (anti-CD3 x anti-CD4 x anti-CD37), (anti-CD3 x anti-CD5 x anti-CD37), and (anti-CD3 x anti-CD8 x anti-CD37), gave minimal lysis and behaved in a similar way to the BsAb, (anti-CD3 x anti-CD37), i.e., no evidence of cooperative signaling for lysis; and group two, containing (anti- T11(1) x anti-CD3 x anti-CD37) and (anti-T11(1) x anti-T11(3) x anti- CD37), which were highly cytotoxic and gave up to 80% specific 51Cr- release. The failure of group one TsAb, in particular (anti-CD3 x anti- CD8 x anti-CD37) which should recruit CD8+ CTL, to give efficient lysis despite having anti-T cell arms that were mitogenic as a bispecific antibody, indicates that the cooperative signaling for proliferation is probably distinct from the signal(s) provided by group two TsAb that activate for both proliferation and lysis.(ABSTRACT TRUNCATED AT 400 WORDS)

This article has been cited by other articles:

				X.-B. Wang, B.-F. Zhao, Q. Zhao, J.-H. Piao, J. Liu, Q. Lin, and H.-L. Huang A New Recombinant Single Chain Trispecific Antibody Recruits T Lymphocytes to Kill CEA (Carcinoma Embryonic Antigen) Positive Tumor Cells In Vitro Efficiently J. Biochem., April 1, 2004; 135(4): 555 - 565. [Abstract] [Full Text] [PDF]

				K. S. Kan, V. A. Anderson, W. S. Leong, A. M. Smith, A. T. Worth, and G. T. Stevenson Thioether-Bonded Constructs of Fab'{{gamma}} and Fc{{gamma}} Modules Utilizing Differential Reduction of Interchain Disulfide Bonds J. Immunol., January 15, 2001; 166(2): 1320 - 1326. [Abstract] [Full Text] [PDF]

				M. K. Wild, W. Strittmatter, S. Matzku, B. Schraven, and S. C. Meuer Tumor Therapy with Bispecific Antibody: The Targeting and Triggering Steps Can Be Separated Employing a CD2-Based Strategy J. Immunol., August 15, 1999; 163(4): 2064 - 2072. [Abstract] [Full Text] [PDF]

				A. L. Tutt, R. R. French, T. M. Illidge, J. Honeychurch, H. M. McBride, C. A. Penfold, D. T. Fearon, R. M. E. Parkhouse, G. G. B. Klaus, and M. J. Glennie Monoclonal Antibody Therapy of B Cell Lymphoma: Signaling Activity on Tumor Cells Appears More Important Than Recruitment of Effectors J. Immunol., September 15, 1998; 161(6): 3176 - 3185. [Abstract] [Full Text] [PDF]

				X. Y. Pei, P. Holliger, A. G. Murzin, and R. L. Williams The 2.0-A resolution crystal structure of a trimeric antibody fragment with noncognate VH-VL domain pairs shows a rearrangement of VH CDR3 PNAS, September 2, 1997; 94(18): 9637 - 9642. [Abstract] [Full Text] [PDF]